Minerva Neurosciences Inc (NERV) has risen sharply, recording gains of 11.38% in the past 4 weeks. However, the stock has corrected -0.51% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 10.24% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 5.23% and the 50-Day Moving Average is 7.29%. Minerva Neurosciences Inc (NASDAQ:NERV): stock turned positive on Friday. Though the stock opened at $10.7, the bulls momentum made the stock top out at $12.28 level for the day. The stock recorded a low of $10.62 and closed the trading day at $11.65, in the green by 8.37%. The total traded volume for the day was 593,094. The stock had closed at $10.75 in the previous days trading.
The company Insiders own 31.33% of Minerva Neurosciences Inc shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 15.26% . Institutional Investors own 36.89% of Minerva Neurosciences Inc shares. Also, Brokerage firm Jefferies maintains its rating on Minerva Neurosciences Inc (NASDAQ:NERV). As per the latest information, the brokerage house raises the price target to $17 per share from a prior target of $10. The shares have been rated Buy. The rating by the firm was issued on May 27, 2016.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. Its lead product candidate is MIN-101, a compound for the potential treatment of patients with schizophrenia. Its product pipeline also includes MIN-117, MIN-202 and MIN-301. MIN-101 is a compound it is developing for the treatment of patients with schizophrenia. MIN-117 is a compound for the potential treatment of patients suffering from major depressive disorder (MDD). MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen for the treatment of insomnia. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinsons disease.